Kalaris Therapeutics will participate in a Fireside Chat at Morgan Stanley's Global Healthcare Conference on September 15, 2026.
Quiver AI Summary
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on retinal disease treatments, has announced its participation in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The chat will feature CEO Andrew Oxtoby and CMO Matthew Feinsod and will take place in New York City. Kalaris is currently conducting a Phase 1b/2 clinical trial for its investigational drug TH103, a dual-action anti-VEGF therapeutic aimed at treating neovascular Age-related Macular Degeneration (nAMD). TH103, developed by Dr. Napoleone Ferrara, boasts enhanced VEGF inhibition and potential applications for various retinal diseases. Kalaris management will also be available for one-on-one meetings during the conference, and additional information can be found on their website.
Potential Positives
- Kalaris Therapeutics will be presenting at a prestigious conference, which may enhance their visibility and credibility in the biopharmaceutical industry.
- The participation of the CEO and CMO in the Fireside Chat indicates strong company leadership and engagement with investors and stakeholders.
- The ongoing Phase 1b/2 study of TH103 demonstrates Kalaris' commitment to advancing innovative treatments for serious retinal diseases, addressing significant unmet medical needs.
Potential Negatives
- Having a management participation in a fireside chat may indicate that the company is in a phase where it needs to actively seek investor interest and confidence in its developments, which may reflect uncertainty or lack of progress in other areas.
- TH103 is still in clinical trial stages, specifically in Phase 1b/2, which suggests that it has not yet received regulatory approval or entered the marketplace, indicating an ongoing risk of development setbacks or failure.
- The press release largely focuses on the company's internal developments without addressing any updates or outcomes from current clinical trials, potentially raising concerns among investors regarding transparency and progress.
FAQ
What is Kalaris Therapeutics known for?
Kalaris Therapeutics is known for developing treatments for prevalent retinal diseases, particularly through innovative biopharmaceutical approaches.
When is the Kalaris Fireside Chat scheduled?
The Kalaris Fireside Chat is scheduled for Tuesday, September 15, 2026, from 4:05 to 4:40 PM EDT.
Who will represent Kalaris at the conference?
Kalaris will be represented by Andrew Oxtoby, the CEO, and Matthew Feinsod, the CMO, during the conference.
What is TH103 and its significance?
TH103 is an investigational dual-targeting biologic designed to treat neovascular Age-related Macular Degeneration (nAMD) with potential best-in-class properties.
How can I arrange a meeting with Kalaris management?
Interested parties can arrange a one-on-one meeting by contacting their conference representative during the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KLRS Insider Trading Activity
$KLRS insiders have traded $KLRS stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $KLRS stock by insiders over the last 6 months:
- SRINIVAS AKKARAJU purchased 244,300 shares for an estimated $1,179,969
- BRETT R HAGEN (Chief Accounting Officer) sold 1,915 shares for an estimated $12,868
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$KLRS Hedge Fund Activity
We have seen 28 institutional investors add shares of $KLRS stock to their portfolio, and 26 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP removed 700,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,849,000
- PROPEL BIO MANAGEMENT, LLC removed 295,771 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,203,787
- UBS GROUP AG added 255,947 shares (+4138.9%) to their portfolio in Q2 2026, for an estimated $1,041,704
- CITADEL ADVISORS LLC added 95,772 shares (+inf%) to their portfolio in Q2 2026, for an estimated $389,792
- GOLDMAN SACHS GROUP INC removed 94,449 shares (-85.5%) from their portfolio in Q2 2026, for an estimated $384,407
- SIMPLIFY ASSET MANAGEMENT INC. removed 87,426 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $355,823
- RENAISSANCE TECHNOLOGIES LLC added 83,200 shares (+125.8%) to their portfolio in Q2 2026, for an estimated $338,624
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$KLRS Analyst Ratings
Wall Street analysts have issued reports on $KLRS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 06/15/2026
To track analyst ratings and price targets for $KLRS, check out Quiver Quantitative's $KLRS forecast page.
$KLRS Price Targets
Multiple analysts have issued price targets for $KLRS recently. We have seen 3 analysts offer price targets for $KLRS in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Yun Zhong from Wedbush set a target price of $17.0 on 05/14/2026
- Jonathan Wolleben from Citizens set a target price of $25.0 on 05/13/2026
- Judah Frommer from Morgan Stanley set a target price of $14.0 on 04/16/2026
Full Release
BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. Kalaris is currently developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascending dose study for neovascular Age-related Macular Degeneration (nAMD).
Details:
- Type : Fireside chat
- Speakers : Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
- Date : Tuesday, September 15, 2026
- Time : 4:05 – 4:40pm EDT
-
Location
: New York, NY
Kalaris management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.
About TH103
TH103 is an investigational dual-targeting biologic with the potential to be best-in class for neovascular and exudative retinal diseases. TH103 was engineered by VEGF scientific discoverer Dr. Napoleone Ferrara to achieve extended intraocular retention with enhanced VEGF inhibition through optimized binding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan (HSPG) anchoring. It is a fully humanized, recombinant fusion protein designed for intravitreal delivery, with potential applications as a treatment for exudative and/or neovascular retinal diseases, such as neovascular Age-related Macular Degeneration (nAMD), diabetic eye disease and retinal vein occlusion. TH103 is currently being investigated in a Phase 1b/2 clinical trial in patients with nAMD.
About Kalaris
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.
For more information, visit
www.kalaristx.com
.
Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
[email protected]
[email protected]
